Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Summary of adverse events experienced by patients in the HOPEFUL-3 study (n = 172)a

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

  ADA continuation group (n = 79) ADA discontinuation group (n = 93) p Valueb
Any adverse event 26 (32.9) 9 (9.7) <0.001
Serious adverse event 3 (3.8) 1 (1.1) 0.33
Infectious adverse event 9 (11.4) 4 (4.3) 0.09
Serious infection 1 (1.3) 0 (0.0) NA
Bronchiolitis 1 (1.3) 0 (0.0) NA
  1. ADA Adalimumab, NA Not applicable
  2. aValues are expressed as n (%)
  3. bStatistical significance as assessed by Fisher’s exact test